Literature DB >> 10813119

Laparostomy for severe intra-abdominal infection complicating colorectal disease.

C M Bailey1, M W Thompson-Fawcett, M G Kettlewell, C Garrard, N J Mortensen.   

Abstract

PURPOSE: The aim of this study was to evaluate the use of laparostomy in the management of patients with severe intra-abdominal infection resulting from colorectal disease.
METHODS: Seven patients, four with inflammatory bowel disease, two with colorectal carcinoma, and one with diverticular perforation, underwent laparostomy during a six-year period for postoperative, severe, intra-abdominal infection.
RESULTS: The median age was 42 years, the mean Acute Physiology and Chronic Health Evaluation II score was 22.7, and the observed mortality was 28.6 percent (2/7 patients). In one patient the laparostomy was closed at 11 days; in all the others the wound was left to heal by granulation and contraction, and two of these later required reconstructive surgery. The median follow-up was three years and seven months.
CONCLUSION: Laparostomy is an effective and practical method of managing patients with severe intra-abdominal infection as a result of colorectal disease.

Entities:  

Mesh:

Year:  2000        PMID: 10813119     DOI: 10.1007/bf02237239

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

Review 1.  Systematic review and meta-analysis of the open abdomen and temporary abdominal closure techniques in non-trauma patients.

Authors:  J J Atema; S L Gans; M A Boermeester
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

2.  Modified Opsite sandwich for temporary abdominal closure: a non-traumatic experience.

Authors:  J M Wilde; M A Loudon
Journal:  Ann R Coll Surg Engl       Date:  2007-01       Impact factor: 1.891

Review 3.  Techniques for Abdominal Wall Closure after Damage Control Laparotomy: From Temporary Abdominal Closure to Early/Delayed Fascial Closure-A Review.

Authors:  Qian Huang; Jieshou Li; Wan-Yee Lau
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.